| 今开：43.74 | 昨收：43.69 |
| 最高：45.58 | 最低：43.13 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：3.714162841E9 |
chuminhua04-16 14:34
4/15，Ultragenyx Pharmaceutical $Ultragenyx(RARE)$ 报告了其实验性 Angelman 综合征治疗药物 GTX-102 的令人鼓舞的早期数据，强化了其在 2022 年以 7500 万美元收购其开发合作伙伴 GeneTx Biotherapeutics 的决定。然而，尽管取得了早期成功，但投资者可能对严重不良反应的报道感到震惊。一些患...查看全文
Ultragenyx(RARE)02-14 23:05
$Ultragenyx药业(RARE)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000080255-24-000711 Act: 34 Size: 6 KB 网页链接查看全文
Ultragenyx(RARE)02-22 06:15
$Ultragenyx药业(RARE)$ S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers Accession Number: 0001193125-24-041577 Act: 33 Size: 1 MB 网页链接查看全文
Ultragenyx(RARE)03-06 09:15
$Ultragenyx药业(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-026629 Size: 10 KB 网页链接查看全文
Ultragenyx(RARE)04-20 04:45
$Ultragenyx(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-046055 Size: 4 KB 网页链接查看全文
Ultragenyx(RARE)02-08 23:25
$Ultragenyx药业(RARE)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902219-24-000136 Act: 34 Size: 37 KB 网页链接查看全文
Ultragenyx(RARE)02-22 05:05
$Ultragenyx药业(RARE)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-017879 Act: 34 Size: 17 MB 网页链接查看全文
Ultragenyx(RARE)03-06 09:25
$Ultragenyx药业(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-026672 Size: 7 KB 网页链接查看全文
Ultragenyx(RARE)03-08 05:15
$Ultragenyx药业(RARE)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-001996 Act: 33 Size: 5 KB 网页链接查看全文
Ultragenyx(RARE)02-08 05:55
$Ultragenyx药业(RARE)$ 144 Report of proposed sale of securities Accession Number: 0002007317-24-000082 Act: 33 Size: 8 KB 网页链接查看全文
Ultragenyx Pharmaceutical(RARE.US)宣布其用于治疗天使综合征(Angelman syndrome)的在研疗法GTX-102在1/2期临床试验中获得的最新数据。数据分析显示，接受GTX-102治疗的扩展队列A和B的患者，在第170天显... 网页链接
瑞信：重申Ultragenyx Pharmaceutical(RARE.US)优于大市评级,目标价96.00美元。 Ultragenyx Pharmaceutical(RARE.US)公司简介：Ultragenyx Pharmaceutical Inc是一家位于美国的生物制药公司。该公司致力于识别，获取，开发和商业化用于治疗... 网页链接
8月30日TuoniaoX.com消息，NFT市场LooksRare发布公告称，虽然以太坊合并后可能会出现分叉版本，但LooksRare协议将不支持它们，这符合以太坊基金会和更广泛的以太坊社区决定的社会共识。且合并前LooksRare.org将进入短暂的 "维护模式"，届时用户... 网页链接
$Ultragenyx(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-046055 Size: 4 KB 网页链接
$Ultragenyx(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-045670 Size: 4 KB 网页链接
$Ultragenyx(RARE)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0000950123-24-003302 Act: 34 Size: 175 KB 网页链接
$Ultragenyx(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-029780 Size: 5 KB 网页链接
$Ultragenyx药业(RARE)$ 144 Report of proposed sale of securities Accession Number: 0001972362-24-000386 Act: 33 Size: 10 KB 网页链接
$Ultragenyx药业(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-029040 Size: 8 KB 网页链接
$Ultragenyx药业(RARE)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-001996 Act: 33 Size: 5 KB 网页链接
$Ultragenyx药业(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-026648 Size: 12 KB 网页链接
$Ultragenyx药业(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-026652 Size: 10 KB 网页链接
$Ultragenyx药业(RARE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-026661 Size: 12 KB 网页链接